Business
Spectral to Present at the Q4 Investor Summit on November 16th
Toronto, Ontario--(Newsfile Corp. - November 15, 2021) - Spectral Medical Inc. (TSX: EDT) (...
About this update from Spectral Medical Inc
[{"type":"text","content":"Spectral to Present at the Q4 Investor Summit on November 16thToronto, Ontario--(Newsfile Corp. - November 15, 2021) - Spectral Medical Inc. (TSX: EDT) (\"Spectral\" or the \"Company\") and its wholly-owned subsidiary, Dialco Medical Inc. (\"Dialco\"), today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021.Chris Seto, Chief Executive Officer of Spectral Medical, is scheduled to present as follows:Event:Q4 Investor SummitDate and Time:Tuesday, November 16 at 8:45 am Eastern TimeWebcast:https://us06web.zoom.us/webinar/register/WN_VDPr29CMR4yCncuW6kF2ogMr. Seto will also host one-on-one meetings with investors throughout the conference.To register and for more information on the conference, please visit www.investorsummitgroup.com.About the Investor SummitThe Investor Summit is an exclusive, independent conference dedicated to connecting small cap and microcap companies with qualified investors. The Q4 Investor Summit will take place virtually, featuring 80+ companies and over 800 investors, consisting of institutional investors, family offices, and private wealth.For more information, please contact Sasha Murray at [email protected] SpectralSpectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (\"PMX\"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 300,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (\"RRT\") across the dialysis spectrum. SAMI is targeting the acute RRT market...